How to Switch Between Different GLP-1s for Weight Loss, According to Experts

Switching Between GLP-1s for Weight Loss Is Common — What Are the Pros and Cons?

Switching Between GLP-1s for Weight Loss Is Common — What Are the Pros and Cons?
Adobe Stock

The saying “If at first you don’t succeed, try, try again” can also apply to GLP-1 medications for overweight and obesity. The first type you try may not be a keeper, for all kinds of reasons.

A study published in 2026 found that about 1 in 5 adults who start a GLP-1 or GLP-1/GIP drug such as semaglutide (Wegovy) or tirzepatide (Zepbound) switch to a different kind within the first year, a change that may be driven by insurance, cost, side effects, or disappointing results.

Even though switching is common, many patients take it as a sign of failure — which isn’t the case, says Allison Rhodes, MD, an assistant professor of medicine who specializes in primary care and obesity medicine at the Ohio State University Wexner Medical Center in Columbus. “A medication change is often simply part of personalizing treatment,” she says.

Dr. Rhodes compares anti-obesity medications to running shoes. “You will always need a pair of shoes to run, but the style that works best for you may change over time,” she says.

Common Reasons for Switching GLP-1 Obesity Drugs

“The most common reason I see patients switch therapies is a change in insurance coverage or formulary status,” says Rhodes.

A change in employment, marriage status, or pharmacy benefits can force someone off a medication that is working, she explains.

Other reasons people make the switch, according to Rhodes:

  • Persistent or intolerable side effects
  • Less weight loss than expected despite appropriate dosing and lifestyle changes
  • A preference for an oral medication rather than an injection
  • Changes in health status, lifestyle, or treatment goals

Issues With Side Effects

People do switch GLP-1s because of side effects like nausea, though Rhodes considers this “a later option rather than a first response.”

Before recommending that patients change to a different GLP-1, physicians will typically aim to reduce side effects by keeping someone at the same dose for longer, for instance, or treating the specific side effect, Rhodes says.

Not Enough Weight Loss

Patients and some physicians may opt to switch a GLP-1 if weight loss slows or temporarily stops. But Rhodes recommends waiting things out.

“The body naturally attempts to reestablish homeostasis [a “steady state”] during weight loss, so plateaus are an expected part of the process,” she says. “Without understanding that physiology, patients and providers may be tempted to switch medications prematurely.”

Social media has created unrealistic expectations, and many patients expect dramatic weight loss on introductory doses. “In reality, these lower doses were designed to improve tolerability, and some individuals do not experience significant weight loss until they have reached higher therapeutic doses,” says Rhodes.

How Often Do Patients Actually Switch GLP-1s?

The 2026 study that looked at patients who switched GLP-1s included nearly 127,000 commercially insured adults with overweight or obesity. The researchers found that about 21 percent changed GLP-1 medications within their first year.

After a year, 36 percent of switchers were still using some type of GLP-1 medication, compared with 21 percent of those who stayed with their first drug.

While the study can’t prove that switching caused people to remain in treatment, it suggests that changing drugs may sometimes be part of keeping treatment going rather than giving up on it.

In Rhodes’s practice, most patients don’t change medications during the first year unless an insurance problem arises or unexpected side effects develop from the early dose increases.

“Discussing cost, side effects, limitations, and treatment goals before starting can help people know what to expect and decide whether the medication is workable for them,” she says.

Can Switching GLP-1s Help People Lose More Weight?

“Whether switching to a different GLP-1 will result in more weight loss really depends on which medication someone is stopping, the strength of the new medication, what they’ve already lost, and how we make the transition in a way that aligns with their goals,” says Yuval Pinto, MD, an obesity and family medicine doctor at Johns Hopkins Medicine in Baltimore.

Some people who have a limited response to one medication may respond better to another. For example, Dr. Pinto has seen patients who lost relatively little weight with semaglutide make more progress after moving to tirzepatide.

That jibes with study results from 2025 that found tirzepatide generally resulted in more weight loss than semaglutide.

“A clinician may also recommend a different drug because it better matches the person’s obesity-related health conditions or the amount of weight loss needed to improve them,” Pinto says.

Switching From an Injection to a Pill for ‘Maintenance’

Sometimes the goal of a switch isn’t necessarily more weight loss but maintaining weight loss while transitioning to a less-expensive medication or an oral GLP-1, says Pinto.

In a 2026 trial, people who’d lost weight with injectable semaglutide or tirzepatide maintained more of that loss after moving to the oral GLP-1 medication orforglipron (Foundayo) than those who stopped active obesity treatment.

But people should be aware that any kind of transition may not be seamless, says Rhodes: “Depending on the medications involved, there may be a temporary period of slower weight loss, stabilization, or even modest weight regain.”

How to Safely Transition to a New GLP-1

Never stop one medication, start another, overlap treatments, or choose a new dose without instructions from your prescriber, Pinto says.

“I tell my patients that these medications are highly potent and can cause severe side effects if they’re mishandled. I compare it to driving a Ferrari: If you hit the gas too hard, it can spin,” he says.

An overly aggressive transition can lead to severe gastrointestinal symptoms, dehydration, inadequate nutrition, or weight loss that is happening too quickly.

There is no standard dose conversion for moving from Wegovy to Zepbound, say, or for changing from an injection to a pill.

According to Pinto, key factors to consider when making any switch include:

  • The person’s reasons for wanting or needing the change
  • The current medication and dose
  • Tolerability of earlier dose increases
  • Any ongoing side effects
  • Overall health and treatment goals
  • Strength and dosing schedule of the new medication

“The first month should be viewed as a transition period,” says Rhodes. During dose escalation, people should track their weight loss progress, side effects, nutrition, and hydration, she says. “This allows problems to be addressed early rather than waiting until symptoms become difficult to manage.”

People who do well after switching GLP-1s also tend to continue the habits that support long-term weight management, Rhodes says, including:

  • Eating enough protein and fiber
  • Staying hydrated
  • Doing resistance training and other physical activity
  • Prioritizing sleep
  • Keeping in touch with their healthcare team

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Xie L et al. Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes. JAMA Network Open. March 10, 2026.
  2. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. May 11, 2025.
  3. Aronne LJ et al. Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial. Nature Medicine. May 13, 2026.

Adam Gilden, MD, MSCE

Medical Reviewer

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me...

Becky Upham, MA

Becky Upham

Author

Becky Upham has worked throughout the health and wellness world for over 25 years. She's been a race director, a team recruiter for the Leukemia and Lymphoma Society, a salesperson...